Rituximab is standard care in a number of lymphoma subtypes, including follicular lymphoma (FL), although many patients are resistant to rituximab, or develop resistance with repeated treatment, and a high proportion relapse. Obinutuzumab is a novel anti-CD20 monoclonal antibody with improved efficacy over rituximab. It is approved for previously untreated chronic lymphocytic leukaemia (CLL), and for use with bendamustine in patients with rituximab-relapsed/refractory FL.
| INTRODUCTION

Follicular lymphoma (FL) is the most common type of indolent non-
Hodgkin lymphoma (iNHL). 1 Lymphomas of this subtype are characterised by an ongoing pattern of relapse and are usually incurable in their advanced stages. [1] [2] [3] Rituximab was the first monoclonal antibody (mAb) to target the CD20 B-cell surface antigen, 4 and its use in conjunction with chemotherapy significantly improved outcomes in patients with advanced (stage 3-4) FL in first-line and salvage settings. [5] [6] [7] [8] [9] [10] Although rituximab is standard care in FL and a number of other lymphoma subtypes, 11 management of rituximab relapse and resistance presents a significant challenge.
12
Obinutuzumab (GA101) is a novel, humanised anti-CD20 mAb. In contrast to rituximab, which works primarily via complementdependent cytotoxicity and localises CD20 in lipid rafts by binding it as a tetramer, 4 obinutuzumab is a type II mAb [13] [14] [15] that binds to CD20 without forming cross-links to CD20 tetramers, and so remains dispersed throughout the entire surface of the B cell. Obinutuzumab is glycoengineered to enhance binding affinity to FcγRIIIA/B expressed on effector cells such as natural killer cells, macrophages/dendritic cells and neutrophils, and works mainly by promoting direct cell death and antibody-dependent cellular cytotoxicity. 4 In clinical trials, obinutuzumab showed improved efficacy compared with rituximab [16] [17] [18] [19] ; in particular, a retrospective pharmacokinetic (PK)/pharmacodynamic (PD) analysis of the CLL11 trial demonstrated that obinutuzumab exhibited superior efficacy over rituximab, regardless of alternative dosing schedules; even when the dose of rituximab was tripled, it could not match the levels of B-cell depletion achieved by obinutuzumab. 20 Obinutuzumab is approved for previously untreated chronic lymphocytic leukaemia (CLL), and for use with bendamustine in patients with rituximab-relapsed/refractory FL. 4 A predictive model describing the population PK of obinutuzumab, based on data from 678 patients with CLL or iNHL, has been described previously. 21 This model used data from 4 clinical studies: CLL11 (NCT01010061; patients with CLL) 22 ; GAUDI (NCT00825149; patients with iNHL) 23 ; GAUGUIN (NCT00517530; patients with CLL, iNHL, diffuse large B-cell lymphoma [DLBCL] or mantle cell lymphoma [MCL]) 18, 24 ; and GAUSS (NCT00576758; patients with CLL, iNHL, DLBCL or MCL). 25 We report the development of an updated model based on a larger database including patients from 2 additional studies: GADOLIN (NCT01059630; patients with rituximab relapsed/refractory iNHL) 26 ; and GATHER (NCT01414855; patients with DLBCL). 27 Our objectives were to further characterise the PK of obinutuzumab in different CD20 B-cell malignancies and to explore whether differences in drug exposure in patients from the GADOLIN study affected PD, safety or efficacy. Table S1 ). Across the studies, obinutuzumab was given intravenously at doses of 50-2000 mg. All studies were carried out in accordance with the Declaration of Helsinki and the International Guidelines for Good Clinical Practice.
| METHODS
| Patients and study designs
Protocols were approved by the ethics committees at participating centres.
| Population PK analysis
The population PK analysis was performed as described previously. 21 The base model, a 2-compartment model in which clearance was a sum of time-dependent clearance (CL T ) and time-independent clearance (CL inf ), was updated with clinical data from the GATHER and GADOLIN studies. GATHER is an open-label phase II trial to evaluate the safety and efficacy of obinutuzumab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy in patients with advanced DLBCL. In GATHER, patients received eight 21-day cycles of obinutuzumab (1000 mg given intravenously on Day 1 of each cycle) alongside standard CHOP therapy for 6
cycles. GADOLIN, a phase III trial to assess the efficacy, safety and PK of obinutuzumab plus bendamustine (G-Benda) vs bendamustine
What is already known about this subject
• Rituximab, a type I anti-CD20 monoclonal antibody, is the current standard of care in follicular lymphoma and a number of other lymphoma subtypes, although management of rituximab relapse and resistance presents a significant challenge.
• Obinutuzumab is a novel, humanised, type II anti-CD20 monoclonal antibody that has exhibited superior efficacy over rituximab, regardless of alternative dosing schedules.
What this study adds
• The study provides a population pharmacokinetic model that accurately describes the pharmacokinetics of obinutuzumab in patients with non-Hodgkin lymphoma and chronic lymphocytic leukaemia.
• No association was found between obinutuzumab exposure and adverse events in rituximab-relapsed/ refractory follicular lymphoma patients, confirming the favourable safety profile of the fixed-dose obinutuzumab regimen that is now approved for use with bendamustine in these patients.
monotherapy in rituximab-refractory iNHL, is described in detail elsewhere. 29, 30 In GADOLIN, a fixed dose of 1000 mg obinutuzumab was given on days Covariates investigated in the model are listed in Table S2 . Graphical evaluation of the models and visual predictive check 32 simulations were performed as described previously. 21 Normalised prediction-distribution-error procedures 33, 34 and stratification of model evaluation diagnostics were also undertaken (Supplementary Methods and Table S3 ). Individual predicted PK parameters were computed and summarised based on the standard iNHL dosing regimen, and individual concentration-time courses simulated (Supplementary Methods).
| Exposure-safety and exposure-efficacy relationships for FL patients (GADOLIN study)
Exposure-safety and exposure-efficacy relationships in rituximabrelapsed/refractory FL patients from the GADOLIN trial were explored using graphical analyses. Among patients with available PK assessments (n = 183), only patients who received at least 5 doses of obinutuzumab (i.e. ≥3 dosing cycles) were included in the analyses.
Baseline patient/disease characteristics of the subpopulation treated with G-Benda who contributed to the PK analysis were consistent with those of the intention-to-treat population. 29, 30 Safety outcomes explored were occurrence of serious adverse events (SAEs), severity of infusion-related reactions (IRRs), occurrence and severity of neutropenia and thrombocytopenia adverse events (AEs) and change in neutrophil/platelet counts. Relationships between exposure and PD outcomes were also explored (Supplementary Methods). Analyses included patients who received ≥1 dose of obinutuzumab.
For the exposure-efficacy analysis, mean obinutuzumab concentration over the induction period (C mean ) was used to represent obinutuzumab exposure as it accounted for the actual dosing history (including dosing delays and modifications) over the entire induction period. This is similar to using cumulative area under the curve (AUC) over induction period, but it better accounts for differences in the duration of induction between patients. This exposure measure has been used previously for obinutuzumab. 35 Minimum serum concentration at a specific timepoint (C trough ) would have been a better predictor of target saturation; however, it mainly accounts for the latest dose before C trough . Distributions of C mean were compared for different best overall response (BOR) categories. Relationships of progression-free survival (PFS) and overall survival (OS) with exposure were assessed by comparing C mean in patients with or without events (progression, relapse, or death for PFS; death for OS). The risk of PFS and OS events associated with 3 categories of exposure (low, medium and high, defined using tertiles of exposure) was compared graphically using Kaplan-Meier plots for all patients (analysis cut-off: 1 September 2014) and for patients with low and high baseline tumour size (defined based on the median value calculated from the sum of the products of diameters of the target lesion; Figure S1 ).
| Cox proportional hazards analysis of PFS and OS
In a post-hoc exploratory analysis, relationships between PK exposure, PFS and OS were characterised by semi-parametric Cox proportional hazards (CPH) models to investigate the effect of potential confound- 
| Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMA-COLOGY, 36 and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18. 
| Population PK analysis in CLL, DLBCL and NHL
A total of 16 301 serum obinutuzumab concentrations from 961 patients were captured for the population PK analysis; 469 of these patients had iNHL, of whom 406 had FL (8545 serum samples) and 183 were from the GADOLIN trial (2178 serum samples).
Other disease types were CLL (n = 342), DLBCL (n = 130) and MCL (n = 20).
Summary statistics for the continuous covariates are presented in Table S4 . The 2-compartment linear model with both linear (CL inf ) and time-dependent clearances (CL T ) described previously 21 accurately described obinutuzumab PK in patients from the 6 clinical studies.
Parameter estimates for the final covariate model are summarised in women, and increased with increasing baseline tumour size (Table 1 ).
Relative to a reference patient (65-year-old female with FL or DLBCL, baseline tumour size 3000 mm 2 ), initial CL T was~100% greater in a patient with high baseline tumour size (22 400 mm 2 ) and 55% lower in a patient with low baseline tumour size (304 mm 2 ). For CL inf , the variance from the reference value was~20% for the same 2 baseline tumour size values (Table 1) .
Several other covariates had an effect on CL inf ; the most marked differences relative to reference values were in patients with MCL, CLL and small lymphocytic lymphoma (Table 1) .
Covariate model evaluation showed no model deficiencies (diagnostic plots) or unaccounted trends (dependencies of random effects).
Visual predictive checks showed good agreement between simulated and observed data for all studies.
Sensitivity analyses were performed by refitting the final model developed on data from the 6 clinical studies from only those patients with iNHL and FL. Population predictions and goodness-of-fit for these 2 models were very similar to those for the final model, and individual predictions were nearly identical.
Summaries of mean PK parameters are shown in Table S6 differ slightly according to lymphoma type, iNHL subtype, weight, sex and baseline tumour size, as well as the accompanying chemotherapy.
| Relationships between exposure and study outcomes in GADOLIN relapsed/refractory FL patients
These analyses used efficacy and safety data from the 145 FL patients from GADOLIN.
| Exposure-safety analysis
Analysis of the relationships between exposure and SAE occurrence were done for all reported SAEs and for seven System Organ Classes in which 4 or more SAEs (occurring at any time) were reported (Table S7 ). Graphical analysis showed no relationship between the severity of IRRs and the predicted obinutuzumab C max after the dose that preceded the IRR ( Figure S4 ). The time course of reductions in neutrophil counts and platelet counts was similar for low (C mean < 293 μg mL −1 ), middle (C mean 293-388 μg mL −1 ) and high (C mean > 388 μg mL Anti-drug antibodies were detected in 1 patient from GADOLIN treated with G-Benda; no influence on obinutuzumab PK was seen.
| Exposure-pharmacodynamic relationships
In all obinutuzumab exposure tertiles, B-cell counts decreased rapidly from baseline after the start of obinutuzumab treatment and remained depressed for the whole observation period (n = 143; data not shown).
The reduction in tumour size between baseline and end of induction was similar across exposure groups with a slightly higher reduction in the middle and high tertiles (median 80%, 86% and 84% in the low, middle and high tertiles, respectively; data not shown)
suggestive of a possible relationship between exposure and tumour burden reduction. However, this might be subject to confounding by higher baseline tumour size in patients with low PK exposure ( Figure S5 ), and is a visual comparison only that was not subject to formal statistical analysis.
| Exploratory exposure-efficacy relationships
Graphical analyses of exposure-efficacy relationships in FL patients who received obinutuzumab in GADOLIN were performed on 128 patients for BOR and PFS. Patients with complete response had apparently higher obinutuzumab C mean than patients in other response categories (partial response, stable disease or progressive disease; Figure S6 ), especially in the subset of patients with low baseline tumour size (below median value).
Patients with PFS events appeared to have a lower median obinutuzumab C mean than patients without events, both for all patients and those with high baseline tumour size; in patients with low baseline tumour size, C mean distributions were similar for patients with and without PFS events (Figure 1 ).
| CPH analysis of exposure-efficacy relationships
The Table 2 . OS data were not analysed by exposure tertiles because of immaturity of the data. Model predictions were in good agreement with observed data for both PFS and OS.
The PFS analysis with continuous exposure confirmed that the risk of a PFS event was lower in the G-Benda arm than the bendamustineonly arm, as previously reported. A CPH model with a categorical exposure (defined by tertiles of C mean ) was also implemented for PFS (Table 2 ). For all 3 exposure groups, risk of progression was significantly lower than for the bendamustine-only arm. However, HRs were not ordered between exposure categories (0.37, 0.45, and 0.30 for low, middle and high exposure categories relative to the bendamustine-only arm) and 95%
CIs overlapped for all 3 categories.
| DISCUSSION
The obinutuzumab population PK model described here is consistent with an earlier model based on a smaller number of CLL and NHL patients, 21 and with previous experience with rituximab that showed time-dependent PK in the targeting of CD20 on B-cells by antibody. [38] [39] [40] The expanded model, based on data from 6 rather than 4 clinical studies (283 additional patients) and examining a greater number of covariates, describes a 2-compartment linear PK model with both time-independent and time-dependent clearance components.
The time-dependent pathway is thought to be due to targetmediated drug disposition. CD20+ B-cells, the therapeutic target of obinutuzumab, also mediate its clearance; as treatment continues, fewer target cells are able to bind to and clear obinutuzumab. Once the majority of target cells are destroyed after being bound by obinutuzumab, target-mediated drug disposition contributes much less to drug clearance. The model showed that clearance increased with increases in baseline tumour size, with a much more profound effect on CL T than CL inf , which is consistent with target-mediated elimination. The model also showed substantial differences in clearance between types of lymphoma. This was most evident for MCL patients, in whom both CL T and CL inf, were higher when compared with a typical FL or DLBCL patient. Rate of clearance decline was also affected by lymphoma type; this may reflect differences between disease types in how CD20 is expressed or distributed 41 and/or the number of circulating lymphocytes in blood. Recently, Tout et al. 47 reported that lower rituximab exposure in Patients in obinutuzumab + bendamustine arm who received <5 obinutuzumab doses (3 cycles) were excluded from this analysis. C mean tertiles: low = 141-313 μg/mL; middle = 313-400 μg/mL; high = 400-794 μg/mL.
*Computed as exp(β).
DLBCL patients was a consequence of high tumour burden leading to poorer prognosis rather than a cause of inferior response. Similarly, exposure-response analyses of trastuzumab in patients with HER2+
cancers suggested that patients with low exposure had shorter overall survival times; however, they also had poor clinical factors at baseline and increasing the dose in this type of patient did not improve efficacy. 48 Exploratory analysis of exposure-efficacy relationships suggested that patients with higher exposure to obinutuzumab could have better efficacy results (BOR, PFS), especially in patients with high tumour burden at baseline; however, this analysis was limited as it did not account for other prognostic factors. These results are consistent with graphical analyses for patients with CLL who received obinutuzumab that similarly were not adjusted for prognostic factors. 21 In cancer patients, exposure-response analyses often indicate poorer response in the low exposure group; however, it is often not a causal relationship as poor prognostic factors lead to low exposure. 48 CPH modelling confirmed that G-Benda treatment significantly increased PFS compared with bendamustine alone in patients with FL, while differences in PFS between obinutuzumab exposure groups (tertiles of C mean ) were small, with overlapping CIs. In addition, bone marrow involvement at baseline significantly shortened both PFS and OS, consistent with the published literature. [49] [50] [51] Increasing age also had a statistically relevant effect on survival (for OS only), in agreement with existing data. 21 Differences in OS between patients with low and high exposure were not meaningful; however, at the time of the analysis cut off (1 May 2015) , OS data were too immature to allow any definite conclusions. These results suggest that the current dosing regimen of obinutuzumab is offering clinical benefit to a majority of FL patients in GADOLIN, irrespective of the variability in drug exposure.
| CONCLUSION
In conclusion, the updated population PK model reported here accurately describes the concentration-time course of obinutuzumab in patients with NHL and CLL, in accordance with earlier findings in this patient population. 21 In rituximab-relapsed/refractory FL patients in the GADOLIN study, no association was found between obinutuzumab exposure and AEs, confirming the favourable safety profile of the fixed-dose regimen that is now approved for use with bendamustine in these patients. Graphical analysis suggested that an increase in obinutuzumab exposure was associated with better response rate and PFS in FL patients, but a multivariate Cox analysis of PFS that accounted for prognostic factors produced less conclusive FIGURE 3 Kaplan-Meier plot, showing relationship between PFS (n = 128) and obinutuzumab exposure (by tertiles of C mean ) in patients with FL participating in GADOLIN who received at least 3 dosing cycles of obinutuzumab (combined with bendamustine). The upper table shows HR for PFS in obinutuzumab plus bendamustine arm relative to control arm (n = 166; bendamustine monotherapy) from the final CPH model. C mean tertile ranges: lower, 141-313 μg/mL; middle, 313-400 μg/mL; higher, 400-794 μg/mL. CI: confidence interval; C mean : mean obinutuzumab exposure over induction period; FL: follicular lymphoma; HR: hazard ratio; PFS: progression-free survival results. These findings confirm the suitability of the recommended fixed dose regimen of 1000 mg of obinutuzumab for rituximabrelapsed/refractory FL that provides clinical benefit in a majority of patients whilst minimising AEs.
